Compare HSBC Holdings plc (HSBC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Repligen Corporation Common Stock — how do they compare? HSBC Holdings plc trades at $95.11 (market cap $322.45B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: HSBC Holdings plc is far larger — about 28.5× Repligen Corporation Common Stock's market cap, and HSBC Holdings plc pays a 3.99% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Repligen Corporation Common Stock for 0 Days on average.
| HSBC | RGEN | |
|---|---|---|
Market Cap | $322.45B | $11.31B |
Volume | 2,058,215 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $107.86 | $194.57 |
52-Week Low | $65.67 | $102.87 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.52B | $11.20B |
Dividend Yield | 3.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with a bearish technical signal from moving averages and ADX. The stock shows solid fundamentals with a P/E of 13.55, net income margin of 34.54%, and recent earnings beats in Q4 2025 and Q2 2026. Recent news highlights strategic expansions in TMT banking and India equity broking, alongside a planned CFO transition in 2027.
The outlook is mixed: valuation appears reasonable and profitability is strong, but technical indicators signal caution and analyst consensus leans Hold. Key risks include execution of growth initiatives and macroeconomic pressures. The stock offers income with a $0.50 dividend, but investors should weigh near-term technical weakness against long-term fundamental strength.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
